Y S Kim

National Cancer Center Korea, Kōyō, Gyeonggi Province, South Korea

Are you Y S Kim?

Claim your profile

Publications (1033)3741.15 Total impact

  • [show abstract] [hide abstract]
    ABSTRACT: To investigate immunity-related guanosine triphosphatase family M (IRGM) genetic variants associated with susceptibility to tuberculosis (TB) in a Korean population. We conducted a prospective case-control study including 193 patients with active TB in Severance Hospital and 230 age- and sex-matched unrelated controls registered in Yonsei Cardiovascular Genome Center. Based on associations with other chronic inflammatory conditions, we analyzed the allele and genotype frequencies of rs72553867, rs10065172, and rs12654043 among patients with TB and healthy controls. The T allele of rs10065172 was significantly associated with protection against developing TB based on allele frequency [P = 0.042; odds ratio (OR) 0.75] and genotype distribution in the codominant model (P = 0.036; OR 0.73). This is the first study to identify a significant association between the IRGM single-nucleotide polymorphism (SNP) rs10065172 and susceptibility to active TB disease in an Asian population. The results suggest that IRGM genetic variants could be associated with susceptibility to active TB disease in the Korean population.
    Infection 03/2014; · 2.44 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Vancomycin is the drug of choice for methicillin-resistant Staphylococcus aureus (MRSA) infection and shows time-dependent bacterial killing. The current study evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of vancomycin and explored its optimal dosing regimens by modeling and simulation. Pharmacokinetics study was performed for 20 patients who were treated with vancomycin intravenously, 1000 mg, every 12 h, and blood for PK was randomly drawn within prespecified time windows. PD study was in vitro time-kill experiment for vancomycin against 20 MRSA strains independent of the PK study, where bacterial titre was measured at 0, 2, 4, 8, 24 h after the beginning of vancomycin exposure at 0, 1, 2, 4, 8, 16, 32× minimum inhibitory concentrations. PK and PD models were built from each data set, and simulation for MRSA titre changes over time in human body was performed for various vancomycin dosing regimens using NONMEM(®) . Vancomycin followed a two-compartment PK model, and creatinine clearance was the significant covariate affecting the clearance of vancomycin. PD model described the in vitro time-kill data well. The PK/PD model predicted clear dose-response relationships of vancomycin. The therapeutic dosing regimens of vancomycin, suggested by the simulation studies, showed good agreement with the current clinical practice guidance, which indicates that this PK/PD modeling and simulation approach could prove useful for identifying optimal dosing regimens of other antibiotics and expediting novel antibiotic development. Using PD model from in vitro time-kill study and human PK model from phase 1 study, we could predict whether the drug is going to be efficacious or obtain insight into the optimal dosing regimens for a novel antibiotic agent in the early phases of drug development process.
    Journal of Clinical Pharmacy and Therapeutics 01/2014; · 2.10 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Oncogenic phosphatidylinositol-3-kinase/serine-threonine kinase (PI3K/AKT) pathway plays a critical role in cell proliferation and growth. Phosphorylated AKT (p-AKT) has been reported to be abnormally overexpressed and to have poor prognostic impact in solid tumors. To define the clinical implications of p-AKT expression in diffuse large B-cell lymphoma (DLBCL), we calculated arbitrary units (AUs) by multiplying the intensity and the proportion of p-AKT expression and investigated the impact of p-AKT expression on clinical outcomes. We assessed 262 patients with DLBCL. Based on a cutoff value of the upper limit of the third quartile of AUs, 56 patients were classified as high p-AKT and the remaining 206 patients were classified as low p-AKT. The high p-AKT group was closely associated with more advanced stage (stage III-IV, P = 0.02), two or more extranodal involvement (P = 0.03), lactic dehydrogenase elevation (P = 0.03), higher International Prognostic Index risk groups (high intermediate/high, P = 0.02), and the presence of B-symptoms (P = 0.01). The high p-AKT group showed substantially worse overall survival (OS) (median OS, 115.0 months versus not reached, P = 0.004) and progression-free survival (PFS) (median PFS, 25.5 versus 105.8 months, P = 0.019) compared with the low p-AKT group. Multivariate analysis revealed that high p-AKT expression retained its significant poor prognostic impact for OS (hazard ratio 1.7; 95% confidence interval, 1.0-2.7; P = 0.031). The subgroup with high p-AKT expression and concurrent Epstein-Barr virus positivity showed worst prognosis with the median OS and PFS of 15.2 and 7.4 months. DLBCL patients with high p-AKT expression showed distinct clinical features and followed a more rapidly deteriorating clinical course with worse OS and PFS. Thus, a more effective treatment option should be developed for this subset of DLBCL patients, and targeting PI3K/AKT pathway may be a promising therapeutic strategy. This study is registered with ClinicalTrials.gov, number NCT01789060.
    Annals of Oncology 01/2014; 25(1):182-8. · 7.38 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Several in vitro studies have been conducted regarding the immunomodulatory and mycobactericidal roles of vitamin D in tuberculous infection. However, discrepancies exist among epidemiological studies. We compared vitamin D deficiency between patients with tuberculosis (TB) and healthy control subjects and identified risk factors for vitamin D deficiency. This was an age- and sex-matched case-control analysis of 94 TB cohort and 282 Korean national survey participants. The median baseline 25-hydroxyvitamin D (25[OH]D) level in the TB group (9.86 ng/ml, IQR 7.19-14.15) was lower than in controls (16.03 ng/ml, IQR 12.38-20.30, P < 0.001). The prevalence of severe vitamin D deficiency was higher in patients with TB (51.1%) than in controls (8.2%, P = 0.001). The median 25(OH)D level increased from 11.40 ng/ml (IQR 7.85-15.73) to 13.18 ng/ml (IQR 10.60-19.71) after treatment completion (P = 0.037). On multivariate analysis, presence of TB and history of TB were independently associated with severe vitamin D deficiency. Patients with TB had a higher prevalence of vitamin D deficiency than control subjects in a Korean population. The median 25(OH)D level increased after TB treatment. Further studies are needed to establish a causal relationship.
    The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 01/2014; 18(1):73-8. · 2.61 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: To investigate the relationship between body mass index (BMI), fat free mass index (FFMI) and obstructive lung disease in Korea. Based on a large population-based, nationwide survey conducted in Korea, 822 subjects with airway obstruction and the same number of healthy control subjects were selected. Spirometry and dual-energy X-ray absorptiometry were used for analysis. Subjects with airway obstruction had a lower mean BMI and FFMI than the control group (23.6 vs. 23.9 kg/m(2) for BMI, P = 0.015 and 17.2 vs. 17.5 kg/m(2) for FFMI, P = 0.013); the BMI (P < 0.001) and FFMI (P < 0.001) values decreased significantly in subjects with severe airway obstruction. The proportion of subjects who were underweight or who had a low FFMI was significantly higher in the severe airway obstruction group (P < 0.001). The decrease in FFMI was more prominent in the lower extremities, followed by the upper extremities and the trunk. Subjects who were underweight had significantly lower one-second forced expiratory volume (FEV1; P = 0.001) and FEV1/forced vital capacity values (P < 0.001). We suggest that lower BMI and FFMI are associated with degree of airway obstruction and that the assessment of BMI and body composition is necessary in patients with severe airway obstruction.
    The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 01/2014; 18(1):102-8. · 2.61 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: This study was conducted to evaluate the relevance of the soluble form of c-Met protein, a truncated form of the c-Met membrane receptor involved in the CagA pathway, as a potential biomarker for gastric cancer. Among 290 gastric cancer case-control sets selected from the Korean Multicenter Cancer Cohort, the plasma concentrations of soluble c-Met protein were measured with enzyme-linked immunosorbent assays. Using analysis of variance and covariance models with age, sex, smoking, Helicobacter pylori infection, and CagA seropositivity, the mean concentrations of soluble c-Met protein between cases and controls were compared. To evaluate the association between gastric cancer and a c-Met protein level, odds ratios and 95% confidence intervals were estimated using conditional logistic regression models. Interactions between CagA-related genes and the soluble c-Met protein concentration were also investigated. The overall median plasma concentration of soluble c-Met among cases was significantly lower than those of controls (1.390 vs. 1.610 ng/mL, p < 0.0001). Closer to the onset of gastric cancer, the soluble c-Met protein level decreased linearly in a time-dependent manner (p for trend = 0.0002). The combined effects between the CagA-related genes and the soluble c-Met protein concentration significantly intensified risks for gastric cancer. Restricted analyses including cases that had been diagnosed within 1 year after entering the cohort had a fair degree of ability (area under the receiver operating characteristic curve of 0.73–0.77) to discriminate gastric cancer cases from normal controls. Our findings demonstrate the potential of the soluble form of c-Met protein as a novel biomarker for gastric cancer. The beneficial effects of a high soluble c-Met concentration in human plasma are strongly supported.
    International Journal of Cancer 10/2013; · 6.20 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: With the increased numbers of kidney transplantations, more patients return to dialysis after graft loss (DAGL). The aim of this study was to investigate the safety and efficacy of peritoneal dialysis (PD) after graft loss compared with transplant-naive PD patients (TN-PD). This study was conducted on 715 patients who started PD between 1988 and 2009, including 47 who started PD after allograft loss (DAGL-PD) and 668 in the (TN-PD) group. The mean ages were 40.8 ± 10.7 in DAGL-PD group and 51.03 ± 14.20 in TN-PD group (P < .01). The most common cause of end-stage renal disease in DAGL was primary glomerulonephritis (76.6%), but it was diabetes mellitus (38.9%) in the TN-PD group (P < .05). Patient survival rates at 1, 5, and 10 years were not different: 100%, 86%, and 57% versus 91%, 70%, and 62%, respectively. PD survival rate at 1, 5, and 10 years did not show significant differences: 98%, 95%, and 88% versus 95%, 80%, and 66%, respectively. The most common causes of death in both groups were infection (DAGL, 26.7%; TN-PD, 24.5%) followed by cardiovascular disease (DAGL, 20.0%; TN-PD, 19.6%); the distribution of causes did not differ significantly (P > .05). The clinical outcomes of PD in DAGL group were comparable with those of TN-PD patients. Therefore, PD could be considered as a dialysis modality for patients who experience allograft failure.
    Transplantation Proceedings 10/2013; 45(8):2949-52. · 0.95 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Investigators conducting diabetes-related research have focused on islet transplantation as a radical therapy for type 1 diabetes mellitus. Pancreatic islet isolation, an essential process, is a very demanding work because of the proteolytic enzymes, species, treatment time, and individual difference. Replacement of primary isolated pancreatic islets must be carried out continuously for various in vitro tests, making primary isolated islets a useful tool for cell transplantation research. Hence, we sought to develop pseudoislets from commercial pancreas-derived cell lines. In this study, we used RIN-5F and RIN-m cells, which secrete insulin, somatostatin, or glucagon. To manufacture hybrid cellular spheroids, the cells were cultured under hanging drop plate and nonadhesive plate methods. We observed that hybrid cellular pseudoislets exhibited an oval shape, with sizes ranging from 590 to 1200 μm. Their morphology was similar to naïve islets. Cell line pseudoislets secreted and expressed insulin, glucagon, and somatostatin, as confirmed by reverse transcriptase polymerase chain reaction, enzyme-linked immunosorbent assay, and immunohistochemistry analyses. Thus, the current artificially manufactured biomimetic pseudoislets resembled pancreatic islets of the endocrine system, appearing as cellular aggregates that secreted insulin, glucagon, and somatostatin. Enhanced immunoisolation techniques may lead to the development of new islet sources for pancreatic transplantation through this pseudoislet strategy.
    Transplantation Proceedings 10/2013; 45(8):3113-7. · 0.95 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Graft nephrectomy is the last-resort option for renal transplant recipients. The aim of this study was to compare the clinical characteristics of patients who underwent graft nephrectomy according to the time after renal transplantation. From 2005 to 2012, 42 patients underwent graft nephrectomy after transplant failure. We divided these patients into early (n = 17) and late graft nephrectomy (n = 25) groups based on graft survival to 6 months, comparing their causes for nephrectomy and clinical characteristics. The patients included 29 men and 13 women, with an overall mean age of 45 years (range, 10-71 years). The main causes for early and late graft nephrectomy were irreversible acute rejection (71%) and graft intolerance syndrome (95%), respectively. The clinical characteristics did not significantly differ between the early and late graft nephrectomy groups except for operative-related complications. Bleeding was more common among patients who underwent early (n = 10) versus late (n = 3) graft nephrectomy (59% vs 12%; P = .01). Of the 10 patients with perioperative bleeding, 8 had a bleeding tendency, such as low platelet count or prolonged prothrombin time at the time of the operation. These complications occurred after antirejection therapy involving plasma exchange or antithymocyte globulin treatment. Allograft nephrectomy was associated with a mortality rate of 2.38%. The cause for graft nephrectomy and type of perioperative complication differed according to timing of graft nephrectomy. Antirejection therapy appeared to contribute to postoperative complications such as bleeding.
    Transplantation Proceedings 10/2013; 45(8):2953-6. · 0.95 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Our objective was to evaluate the usefulness of three-dimensional (3-D) contrast-enhanced (CE) magnetic resonance angiography (MRA) to assess renal parenchyma, arterial inflow stenosis, and peritransplant fluid collections in the early period after kidney transplantation (KT). Between January 2010 and April 2011, we examined a consecutive series of 144 renal transplants using 3-D CE MRA at 14 days after KT. MRA showed parenchyma infarctions (n = 17, 11.8%), arterial inflow stenoses (n = 23, 16%), lymphoceles (n = 14, 9.7%), and hematomas (n = 6, 4.2%). The degree of renal transplant artery inflow stenosis was graded qualitatively based on diameter criterion; <50% = mild, 50% to 70% = moderate, and >70% = severe in 10 (6.9%), 5 (3.5%), and 8 (5.6%) subjects, respectively. The study recipients were divided into 3 groups according to the degree of renal artery inflow stenosis (group I: normal; group II: mild and moderate, <70%; group III: severe, >70%). Among group III patients who underwent digital subtraction angiography, 5 had percutaneous transluminal angioplasty or stenting performed after 1 month. Their mean resume creatinine levels at 1, 6, and 12 months after transplantation were not significantly different from those in the other groups (P = .391, .447, .110). The prevalence of graft loss (n = 2) was high in group III (P = .012), although the frequency of acute rejection episodes was not different among the groups (P = .890). The incidences of renal parenchyma infarction, peritransplant fluid collection and arterial inflow stenosis were unexpectedly high in the early period after KT. Thus, 3-D CE MRA provided a rapid global assessment of the renal parenchyma, transplant arterial system, and peritransplant fluid collection that can be helpful to detect or exclude many causes of renal transplant dysfunction.
    Transplantation Proceedings 10/2013; 45(8):2925-30. · 0.95 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Frequency modulation reflectometer has been developed to measure the plasma density profile of the Korea Superconducting Tokamak Advanced Research tokamak. Three reflectometers are operating in extraordinary polarization mode in the frequency range of Q band (33.6-54 GHz), V band (48-72 GHz), and W band (72-108 GHz) to measure the density up to 7 × 10(19) m(-3) when the toroidal magnetic field is 2 T on axis. The antenna is installed inside of the vacuum vessel. A new vacuum window is developed by using 50 μm thick mica film and 0.1 mm thick gold gasket. The filter bank of low pass filter, notch filter, and Faraday isolator is used to reject the electron cyclotron heating high power at attenuation of 60 dB. The full frequency band is swept in 20 μs. The mixer output is directly digitized with sampling rate of 100 MSamples/s. The phase is obtained by using wavelet transform. The whole hardware and software system is described in detail and the measured density profile is presented as a result.
    The Review of scientific instruments 08/2013; 84(8):084702. · 1.52 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Many obstacles beset islet transplantation, particularly insufficient tissue mass. Previously, we reported production of pseudo-islets. In addition, there have been reports in which coculture with pancreatic islet and bone marrow mesenchymal stem cells (BMSCs) demonstrated positive effects on pancreatic islet function. The purpose of this study was to perform morphologic and functional evaluations of pancreatic pseudo-islets cocultured with BMSCs. Pancreatic endocrine cells (PECs) were collected with a previously reported method; bone marrow was aspirated from the rat femur. Subsequently, PECs and BMSCs cocultured at high density on low-cell-binding culture dishes kept suspended by shaking. The functionality and characteristics of the mixed cell complexes were evaluated by glucose challenge, insulin enzyme-linked immunosorbent assay, reverse-transcription polymerase chain reaction, and immunohistochemistry. Through expansion for 2 weeks in continuous culture passages, ∼1 million PECs were recovered after aggregation. They presented spherical shapes and sizes similar to naïve islets, according to phase-contrast microscopy. The spheroid aggregates of pancreatic islet cells and BMSCs showed fortified functions and maintained viability. In conclusion, PECs served as a cell source for pseudo-islets, which were both morphologically and genetically similar to naïve islets. We also suggest a manufacturing method for mixed cellular complexes from 2 different origins that can improve secretion ability and cell differentiation.
    Transplantation Proceedings 06/2013; 45(5):1885-8. · 0.95 Impact Factor
  • Source
    MS Lee, KH Park, MH Jung, YS Kim
    Antimicrobial Resistance and Infection Control. 06/2013; 2(1).
  • Source
    MS Lee, KH Park, MH Jung, YS Kim
    Antimicrobial Resistance and Infection Control. 06/2013; 2(1).
  • [show abstract] [hide abstract]
    ABSTRACT: BACKGROUND: Herpes zoster (HZ) is a common infectious disease after kidney transplantation (KT). The incidence of HZ may increase during cytomegalovirus (CMV) preemptive therapy. We therefore evaluated the incidence, risk factors, and clinical outcomes of HZ after KT, according to the type of CMV prophylaxis used. METHODS: We retrospectively established a cohort of KT recipients who underwent transplantation from June 2008 to May 2010. Patients were categorized into 3 groups according to CMV prophylaxis regimen: Group A (preemptive therapy), Group B (universal prophylaxis <3 months), and Group C (universal prophylaxis >3 months). The incidence rate of HZ was compared in each group, and risk factors for HZ were identified. RESULTS: The incidence rate of HZ was 46.6 (95% confidence interval [CI] 31.4-66.5) per 1000 person-years. The incidence rate was higher in Group A than in Group C (80.0 vs. 13.0 per 1000 person-years; P = 0.001). Median onset time of HZ after KT was shorter in Group A than in Group B (0.9 vs. 9.9 months; P < 0.001) and Group C (0.9 vs. 14.8 months; P = 0.008). Post-herpetic neuralgia occurred in 7 patients (23%). No visceral involvement or death was related to HZ. By multivariate analysis, only female gender (corrected relative risk 1.59; 95% CI 1.09-2.00) was independently associated with HZ development. CONCLUSIONS: In the setting of CMV preemptive therapy, a differentiated varicella zoster virus-specific prophylaxis might be necessary for patients with HZ risk factors.
    Transplant Infectious Disease 05/2013; · 1.98 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Health care-associated pneumonia (HCAP) affects a heterogeneous group of patients in frequent contact with health care systems. However, HCAP criteria poorly predict infection with drug-resistant (DR) pathogens. To validate our previously reported risk-scoring model (predictive of DR pathogen infection) in patients admitted to hospital with pneumonia. We evaluated 580 patients admitted with culture-positive bacterial pneumonia. We identified risk factors, evaluated the risk-scoring model's capacity to predict infection by DR pathogens and compared the model's diagnostic accuracy with that of current HCAP criteria. DR pathogens were observed in 227/580 patients (39.1%). Of 269 HCAP patients, 153 (56.9%) were infected with DR pathogens. Overtreatment was more common in HCAP than in community-acquired pneumonia (58.7% vs. 41.2%, P < 0.001). Recent hospitalisation, admission from a long-term care facility, recent antibiotic treatment and tube feeding were independently associated with DR pathogens. For pathogen prediction, the risk-scoring model showed better diagnostic accuracy than HCAP criteria (area under receiver operating-characteristic curve = 0.723 vs. 0.673, P < 0.001). According to current HCAP criteria, half of the HCAP patients were treated unnecessarily with broad-spectrum antibiotics. Risk scoring by stratifying risk factors could improve the identification of patients likely to be infected with DR pathogens.
    The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 05/2013; 17(5):704-9. · 2.61 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: BACKGROUND: There is controversy regarding the best method and benefit of cardiac evaluation of asymptomatic renal transplant candidates. The positive predictive value of ischemia on a noninvasive stress test was ∼5%-10% in Kidney Disease Outcomes Quality Initative (KDOQI), American Society of Transplantation (AST), and Lisbon guidelines. We compared prediction of cardiac events with the use of simple transthoracic echocardiography versus a noninvasive stress test in asymptomatic candidates. METHODS: We selected asymptomatic patients with good functional capacity who would be recommended a cardiac stress test by both KDOQI and AST guidelines, we excluding those with a history of cardiovascular disease. Group A (n = 124) underwent only echocardiography, and group B (n = 41) underwent echocardiography and noninvasive stress test. We measured the incidences of cardiac events and cardiac death within 3 years after transplantation. RESULTS: The mean age of group A was 39 ± 7 and group B 40 ± 5 years. Diabetic patients among groups A and B were 8.8% (11/124) and 9.7% (4/41), respectively. The mean duration of dialysis was 2.9 ± 5 years. Only 4 group B patients showed a positive result on the noninvasive stress test, but they had no obstructive disease on coronary angiograms. The incidences of ischemic heart disease after transplantation of groups A and B were 4% (5/124) and 4.8% (2/41), respectively (P = .88). There was no death due to cardiac events in either group. CONCLUSIONS: In this study, simple echocardiography showed an ability similar to stress test to predict ischemic heart disease in asymptomatic renal transplant candidates with good functional capacity, relatively younger age, lower prevalence of diabetes, and shorter duration of dialysis.
    Transplantation Proceedings 05/2013; 45(4):1371-1373. · 0.95 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: BACKGROUND: Laparoscopic fenestration (LF) and percutaneous catheter drainage (PCD) are widely accepted treatments for symptomatic lymphoceles. The aim of this study was to review the results and compare the outcomes of LF with those of PCD. PATIENTS AND METHODS: Among 1363 patients who underwent kidney transplantation at our institute between 1999 and 2011, 35 (2.5%) developed symptomatic lymphoceles. Among them, 7 were treated by LF after PCD; 10, LF only, and 18 PCD only. The patients were divided into 2 groups based upon the treatment method: LF (n = 17) and PCD-only groups (n = 18). RESULTS: No intergroup differences in age, gender, diabetes prevalence, retransplant rate, delayed graft function, or serum creatinine was observed at 7 days after the treatment. However, acute rejection episodes and sirolimus use were more frequent among the LF group (P = .028). Furthermore, median drainage on the first day was significantly greater in the LF versus PCD group. After catheter insertion, the PCD group showed a significant decrease in drainage on the following day, but no decrease was observed in the LF group. CONCLUSIONS: LF is a safe treatment for symptomatic lymphocele. LF should be held in reserve for treatment failures after PCD. LF seems to be a more reasonable first-line treatment for symptomatic lymphoceles in patients at high risk for graft dysfunction.
    Transplantation Proceedings 05/2013; 45(4):1667-1670. · 0.95 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Background:Surrogate biomarkers for metastatic colorectal cancer (mCRC) are urgently needed to achieve the best outcomes for targeted therapy.Methods:A clinical association analysis was performed to examine the three single-nucleotide polymorphisms (SNPs) that were previously proposed as markers of chemosensitivity to the cetuximab (124 patients) and bevacizumab regimens (100 patients) in mCRC patients. In addition, biological correlations were examined for the candidate SNPs in terms of their regulatory pathway.Results:For cetuximab regimens, patients homozygous for the wild-type alleles (GG) of LIFR rs3729740 exhibited a 1.9 times greater overall response rate (ORR) and 1.4 months longer progression-free survival (PFS) than those homozygous or heterozygous for the mutant allele (GA and AA; P=0.022 and 0.027, respectively). For bevacizumab regimens, patients homozygous for the minor alleles (TT) of ANXA11 rs1049550 exhibited an ORR twice as high as those homozygous or heterozygous for the ancestral allele (CC and CT; P=0.031). Overall response rate gain was achieved up to 10% in patients with wild-type LIFR rs3729740 patients either with wild-type KRAS or skin toxicity (P=0.001) respectively. Specifically in clones treated with cetuximab and bevacizumab regimens, active p-ERK and MMP-9 expressions were significantly reduced in clones expressing wild-type LIFR rs3729740 (P=0.044) and in those expressing minor-type ANXA11 rs1049550 (P=0.007), respectively.Conclusion:LIFR rs3729740 and possibly ANXA11 rs1049550 may be useful as biomarkers for predicting whether mCRC patients are sensitive to relevant target regimens, although further validation in large cohorts is needed.British Journal of Cancer advance online publication, 11 April 2013; doi:10.1038/bjc.2013.163 www.bjcancer.com.
    British Journal of Cancer 04/2013; · 5.08 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: AIM: To investigate the computed tomography (CT) findings in patients with stage IE/IIE extranodal natural killer/T-cell lymphoma (ENKTL) arising in the nasal cavity and to evaluate whether imaging findings revealed by CT have prognostic value. MATERIALS AND METHODS: The CT findings of 62 patients diagnosed with IE/IIE ENKTL arising in the nasal cavity were retrospectively reviewed. Imaging findings were investigated, and evaluated imaging findings were analysed for the prognostic value of overall survival (OS) and disease-free survival (DFS). RESULTS: Of the 62 patients, 21 (34%) presented with a superficial infiltrative, 38 (61%) with a mass forming, and three (5%) with a combined pattern. Of all imaging findings, local invasiveness (n = 26, 42%), including bony destruction, erosion, or soft-tissue involvement, was the only independent prognostic factor for OS [p = 0.008; hazard ratio (HR): 3.85; 95% confidence intervals (CI): 1.42-10.44] and DFS (p = 0.001; HR: 4.25; 95% CI: 1.72-10.47). In a subgroup analysis of 36 cases with no local invasiveness, a superficial infiltrative pattern in one nasal cavity was a positive prognostic factor for OS (p = 0.028) and DFS (p = 0.008). CONCLUSION: Imaging findings at CT provided clinically useful predictions for treatment outcomes. Local invasiveness revealed by CT findings was a strong prognostic factor for poor OS and DFS. In addition, in patients with no local invasiveness, a superficial infiltrative pattern in one nasal cavity predicted favourable OS and DFS.
    Clinical radiology 03/2013; · 1.65 Impact Factor

Publication Stats

17k Citations
3,741.15 Total Impact Points

Institutions

  • 2013
    • National Cancer Center Korea
      Kōyō, Gyeonggi Province, South Korea
    • Korea Astronomy and Space Science Institute
      Sŏul, Seoul, South Korea
  • 1993–2013
    • Asan Medical Center
      • Department of Urology
      Sŏul, Seoul, South Korea
    • University of Ulsan
      • • College of Medicine
      • • Department of Materials Engineering
      • • Department of Family Medicine
      Urusan, Ulsan, South Korea
  • 1992–2013
    • Yonsei University
      • • Research Institute for Trasplantation
      • • Department of Biochemistry
      • • Department of Internal Medicine
      Sŏul, Seoul, South Korea
    • Mount Sinai School of Medicine
      • Department of Medicine
      Manhattan, NY, United States
  • 2012
    • Konkuk University Medical Center
      Changnyeong, South Gyeongsang, South Korea
    • Chung-Ang University
      Sŏul, Seoul, South Korea
    • Kosin University
      Tsau-liang-hai, Busan, South Korea
  • 2011–2012
    • Konkuk University
      • • Department of Laboratory Medicine
      • • School of Physics
      Sŏul, Seoul, South Korea
    • Chung-Ang University Hospital
      Sŏul, Seoul, South Korea
    • Hanil General Hospital
      Sŏul, Seoul, South Korea
    • National Fusion Research Institute
      Daiden, Daejeon, South Korea
  • 2001–2012
    • Kyung Hee University Medical Center
      • Department of Endocrinology and Metabolism
      Seoul, Seoul, South Korea
    • Korean Institute of Geoscience and Mineral Resources
      Sŏul, Seoul, South Korea
    • Chonbuk National University
      • Semiconductor Physics Research Center
      Seoul, Seoul, South Korea
  • 2000–2012
    • Korea Atomic Energy Research Institute (KAERI)
      Daiden, Daejeon, South Korea
    • Minneapolis Veterans Affairs Hospital
      Minneapolis, Minnesota, United States
    • Kunsan National University
      • Department of Physics
      Gunzan, North Jeolla, South Korea
    • Hallym University Medical Center
      • Department of Plastic and Reconstructive Surgery
      Seoul, Seoul, South Korea
  • 1998–2012
    • Ulsan University Hospital
      Urusan, Ulsan, South Korea
    • University of California, San Diego
      • Department of Radiology
      San Diego, CA, United States
  • 1993–2012
    • Catholic University of Korea
      • • Department of Internal Medicine
      • • Department of Pharmacology
      Seoul, Seoul, South Korea
  • 1988–2012
    • Kyung Hee University
      • • Department of Medicine
      • • College of Medicine
      Sŏul, Seoul, South Korea
  • 2002–2011
    • Pusan National University
      • • Department of Nuclear Medicine
      • • Department of Internal Medicine
      • • Department of Microbiology
      Pusan, Busan, South Korea
  • 2001–2011
    • Sungkyunkwan University
      • • Department of Surgery
      • • School of Medicine
      • • School of Advanced Materials Science and Engineering (AMSE)
      • • Centre of Advanced Materials Technology Research
      Sŏul, Seoul, South Korea
  • 1995–2011
    • Seoul National University Hospital
      • • Department of Internal Medicine
      • • Department of Neuropsychiatry
      Seoul, Seoul, South Korea
    • Pohang Accelerator Laboratory
      Urusan, Ulsan, South Korea
  • 1992–2011
    • Yonsei University Hospital
      • • Department of Internal Medicine
      • • Surgery
      Seoul, Seoul, South Korea
  • 2010
    • Chungbuk National University
      Chinsen, North Chungcheong, South Korea
    • University of Adelaide
      • School of Electrical and Electronic Engineering
      Adelaide, South Australia, Australia
    • Pohang University of Science and Technology
      • Department of Life Sciences
      Andong, North Gyeongsang, South Korea
    • Daewoo Shipbuilding and Marine Engineering
      Sŏul, Seoul, South Korea
  • 2004–2010
    • Andong National University
      Antō, North Gyeongsang, South Korea
  • 1996–2010
    • Hallym University
      • College of Medicine
      Sŏul, Seoul, South Korea
    • Georgia Institute of Technology
      • School of Civil & Environmental Engineering
      Atlanta, Georgia, United States
  • 1994–2010
    • Korea University
      • • Department of Computer and Communications Engineering
      • • Department of Internal Medicine
      • • Department of Pathology
      • • Department of Anatomy
      Seoul, Seoul, South Korea
    • Institut de Génétique et de Biologie Moléculaire et Cellulaire
      Strasburg, Alsace, France
  • 2008
    • Dongguk University
      • Department of Internal Medicine
      Sŏul, Seoul, South Korea
    • Korea Food Research Institute
      Sŏngnam, Gyeonggi Province, South Korea
  • 2004–2008
    • Myongji University
      • Department of Electronics Engineering
      Sŏul, Seoul, South Korea
  • 2002–2008
    • Ewha Womans University
      • Department of Surgery
      Sŏul, Seoul, South Korea
  • 2001–2008
    • Chosun University
      • College of Pharmacy
      Gwangju, Gwangju, South Korea
  • 1999–2008
    • Ajou University
      • • Department of Surgery
      • • Department of Gastroenterology
      Seoul, Seoul, South Korea
    • Incheon St. Mary’s Hospital, Catholic Medical Center
      Bucheon, Gyeonggi Province, South Korea
    • Chiba University
      • Faculty of Pharmaceutical Sciences
      Chiba-shi, Chiba-ken, Japan
  • 2007
    • Eulji University
      Sŏul, Seoul, South Korea
  • 1995–2007
    • Soonchunhyang University
      • College of Medicine
      Onyang, South Chungcheong, South Korea
  • 1993–2007
    • Soon Chun Hyang University Hospital
      • Department of Gastroenterology
      Sŏul, Seoul, South Korea
  • 2001–2006
    • Samsung Advanced Institute of Technology
      Usan-ri, Gyeonggi Province, South Korea
  • 2005
    • Myongji Hospital
      Kōyō, Gyeonggi Province, South Korea
  • 1993–2005
    • Seoul National University
      • • College of Pharmacy
      • • Department of Internal Medicine
      • • College of Medicine
      Seoul, Seoul, South Korea
  • 2003
    • Hongik University
      • Department of Science
      Sŏul, Seoul, South Korea
  • 1999–2003
    • Hanyang University Medical Center
      Sŏul, Seoul, South Korea
  • 1997–2003
    • Hanyang University
      • • Department of Nuclear Engineering
      • • College of Medicine
      • • Major in Internal Medicine
      Sŏul, Seoul, South Korea
    • National Human Genome Research Institute
      Maryland, United States
    • Osaka City University
      • First Department of Surgery
      Ōsaka, Ōsaka, Japan
    • National Institutes of Health
      • Branch of Metabolic Diseases Branch (MDB)
      Bethesda, MD, United States
    • Korea Advanced Institute of Science and Technology
      Sŏul, Seoul, South Korea
    • Harvard Medical School
      • Department of Pediatrics
      Boston, MA, United States
  • 1996–2003
    • University of Seoul
      Sŏul, Seoul, South Korea
    • Kagoshima University
      • • Division of Pathology
      • • Faculty of Medicine
      Kagosima, Kagoshima, Japan
  • 1980–2003
    • University of California, San Francisco
      • • Veterans Affairs Medical Center
      • • Division of Hospital Medicine
      • • Department of Anatomy
      San Francisco, California, United States
  • 2001–2002
    • Korea Basic Science Institute KBSI
      Sŏul, Seoul, South Korea
  • 1998–2001
    • Konyang University
      • College of Medicine
      Nonsan, South Chungcheong, South Korea
    • Université des Sciences et Technologies de Lille 1
      • Unité de Glycobiologie Structurale et Fonctionnelle (UGSF)
      Lille, Nord-Pas-de-Calais, France
  • 1993–2001
    • National Cancer Institute (USA)
      • Laboratory of Pathology
      Maryland, United States
  • 1998–2000
    • Inha University
      • Department of Biochemistry
      Seoul, Seoul, South Korea
  • 1995–2000
    • University of Iowa
      • • Department of Chemistry
      • • Department of Orthopaedics and Rehabilitation
      Iowa City, IA, United States
  • 1990–2000
    • University College London
      Londinium, England, United Kingdom
  • 1995–1999
    • International St. Mary's Hospitals
      Chemulpo, Incheon, South Korea
  • 1980–1999
    • San Francisco VA Medical Center
      San Francisco, California, United States
  • 1997–1998
    • The National Institute of Diabetes and Digestive and Kidney Diseases
      Maryland, United States
  • 1972–1997
    • CSU Mentor
      Long Beach, California, United States
  • 1994–1996
    • University of Minnesota Twin Cities
      • Department of Medicine
      Minneapolis, MN, United States
  • 1994–1995
    • Soroka Medical Center
      • Department of Gastroenterology
      Be'er Sheva`, Southern District, Israel
  • 1992–1993
    • University of Minnesota Duluth
      • Medical School
      Duluth, Minnesota, United States
  • 1986–1988
    • New York State Institute for Basic Research in Developmental Disabilities
      • Department of Psychology
      New York City, New York, United States